Gao Ying-Chun, Wu Jie
Department of Gynaecology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, 223300, China.
Tumour Biol. 2015 Jun;36(6):4843-50. doi: 10.1007/s13277-015-3138-3. Epub 2015 Feb 1.
Ovarian cancer is the fifth leading cause of female death globally due to its low survival rates. Thus, improved approaches for ovarian cancer detection are urgently needed. MicroRNAs as a new class of biomarkers have been explored in recent studies. This study was trying to identify and validate the two kinds of serum microRNA (miR-200c and miR-141) as biomarkers for ovarian cancer. We extracted serum samples from 74 epithelial ovarian cancer patients, 19 borderline ovarian cancer, and 50 healthy controls. Relative expression of these miRNA markers were measured by quantificational real-time polymerase chain reaction assay (qRT-PCR). Receiver operating characteristics (ROC) and area under the ROC curve (AUC) were used to validate the diagnostic value of miR-200c and miR-141. Kaplan-Meier curve and the log-rank test were conducted to detect the prognostic value of miR-200c and miR-141. miR-200c and miR-141 were significantly elevated in the epithelial ovarian cancer patients compared to healthy controls. The relative expression level of miR-200c showed a descending trend from early stages to advanced stages, while the level of miR-141 displayed an escalating trend. Patients with high miR-200c level achieved significantly a higher 2-year survival rate compared with the other group (P < 0.001), while low miR-141 group showed a significantly higher survival rate. The results of the current study suggested that serum miR-200c and miR-141 were able to discriminate the ovarian cancer patients from healthy controls. In addition, miR-200c and miR-141 may be predictive biomarkers for ovarian cancer prognosis. Further large-scale studies are still needed to confirm our findings.
卵巢癌因其低生存率成为全球女性死亡的第五大主要原因。因此，迫切需要改进卵巢癌的检测方法。微小RNA作为一类新型生物标志物，在最近的研究中已被探索。本研究试图鉴定并验证两种血清微小RNA（miR - 200c和miR - 141）作为卵巢癌的生物标志物。我们从74例上皮性卵巢癌患者、19例卵巢交界性肿瘤患者和50例健康对照者中提取血清样本。通过定量实时聚合酶链反应测定法（qRT - PCR）测量这些miRNA标志物的相对表达。采用受试者工作特征（ROC）和ROC曲线下面积（AUC）来验证miR - 200c和miR - 141的诊断价值。进行Kaplan - Meier曲线和对数秩检验以检测miR - 200c和miR - 141的预后价值。与健康对照相比，上皮性卵巢癌患者中miR - 200c和miR - 141显著升高。miR - 200c的相对表达水平从早期到晚期呈下降趋势，而miR - 141的水平呈上升趋势。miR - 200c水平高的患者与另一组相比，2年生存率显著更高（P < 0.001），而miR - 141水平低的组显示出显著更高的生存率。本研究结果表明，血清miR - 200c和miR - 141能够区分卵巢癌患者和健康对照。此外，miR - 200c和miR - 141可能是卵巢癌预后的预测生物标志物。仍需要进一步的大规模研究来证实我们的发现。
